arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

ARDELYX, INC.

ARDX
$4.00 ▼ -0.88 (-17.97%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
15 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

ARDELYX, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $964.1M
Dividend Yield
Revenue Growth 22.1%
Op. Margin -10.1%
ROIC -11.3%
FCF / Share $-0.18
Trailing P/E
Price / Book 5.9x
FCF Yield
Debt / Equity 1.21
info Valuation on last close. End-of-day price, Aug 7, 2026.

15-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$407.32M
↑ +22.1%
Net Income Profit after all expenses
$-61.60M
↓ -57.4%
Operating Margin Operating profit as % of sales
-10.1%
↓ -20.1% 15th
FCF / Share Free cash flow per share
$-0.18
↑ +6.3%
Long-Term Debt Long-term obligations
$202.83M
↑ +34.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
13
Returns
20
Financial Health
32
Cash Quality
49

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 55 quarters